A Phase 2 Study Of LY2835219 For Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Trial Profile

A Phase 2 Study Of LY2835219 For Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Abemaciclib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms MONARCH 1
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Jul 2017 According to an Eli Lilly media release, the U.S. Food and Drug Administration (FDA) has granted Priority Review for NDA application for abemaciclib monotherapy for patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who had prior endocrine therapy and chemotherapy for metastatic disease.This NDA submission was based on the data from this trial.
    • 06 Jun 2017 Results assessing the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 22 May 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top